Sushmita Datta1,
Terrell D. Staewen1, Priya Goel1, Stacy S. Cofield2,
Gary R. Cutter2, Fred D. Lublin3, Jerry S. Wolinsky4,
Ponnada A. Narayana1
1Diagnostic
and Interventional Imaging, Medical School, The University of Texas Health
Science Center at Houston, Houston, TX, United States; 2Biostatistics,
University of Alabama at Birmingham, Birmingham, AL, United States; 3The
Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School
of Medicine, New York, NY, United States; 4Neurology, Medical
School, The University of Texas Health Science Center at Houston, Houston,
TX, United States
Gray matter (GM) atrophy in multiple sclerosis represents neurodegeneration and appears to correlate with clinical measures. In this study, we implemented Tensor based morphometry (TBM) to assess regional gray matter atrophy in 250 MS subjects that were randomly chosen from a total of 1008 subjects who participated in a multi-center clinical trial. Significant atrophy was observed in various GM regions including major deep GM structures.